Navigation Links
Analysis Shows BYDUREON™ Was Not Associated with Clinically Relevant QT Prolongation in Patients with Type 2 Diabetes: Results Presented at ADA 2011
Date:6/24/2011

ess release due to a number of risks and uncertainties, including the risk that the analysis mentioned in this press release may not be predictive; BYDUREON may not be approved by the FDA as soon as anticipated or at all; the companies' response to the FDA's complete response letter may not be submitted in a timely manner and/or the information provided in such response may not satisfy the FDA; the QT study mentioned in this press release may not produce the results we expect; the FDA may request additional information prior to approval; BYETTA and/or the approval of BYDUREON and the revenues generated from these products may be affected by competition; unexpected new data; safety and technical issues; clinical trials not being completed in a timely manner, not confirming previous results, not being predictive of real world use or not achieving the intended clinical endpoints; label expansion requests or NDA filings not receiving regulatory approval; the commercial launch of BYDUREON being delayed; or manufacturing and supply issues. The potential for BYETTA and/or BYDUREON may also be affected by government and commercial reimbursement and pricing decisions, the pace of market acceptance, or scientific, regulatory and other issues and risks inherent in the development and commercialization of pharmaceutical products including those inherent in the collaboration with and dependence upon Amylin, Lilly and/or Alkermes. These and additional risks and uncertainties are described more fully in Amylin's, Lilly's and Alkermes' most recent SEC filings including their Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Amylin, Lilly and Alkermes undertake no duty to update these forward-looking statements.

BYDUREON™ and BYETTA® are trademarks of Amylin Pharmaceuticals, Inc. All other marks are the marks of their respective owners.

P-LLY

(i)  Long QT Syndrome. Heart Rhythm Society. Availab
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Alkermes, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Analysis Compares Cost-Effectiveness of Premixed Insulin Analogs to Long-Acting Insulin Analogs in the Long-Term Treatment of Type 2 Diabetes in the U.S.
2. Analysis Finds BYETTA® Associated with Lower Likelihood of Heart Failure Compared with Other Diabetes Therapies: Results Presented at ADA 2011
3. PRA Early Phase Leaders to Speak at Bioanalysis Forum
4. Dr. Assad Al-Ammar Joins Irvine Pharmaceutical Services as the New Minerals Analysis Manager in Response to the Growing Needs for USP Elemental Impurities Testing
5. Reportlinker Adds Distributor Analysis of the Pharmaceutical Industry in Key SADC Countries
6. Post Hoc Analysis from RECOVER Study Examined Effects of Neupro® (Rotigotine Transdermal System) on Surrogate Markers of Mood and Anhedonia in Parkinsons Disease
7. ForteBio Introduces New Biosensor for Kinetic Analysis and Screening of Mouse IgG Antibodies
8. Hip Resurfacing Implants - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
9. Reportlinker Adds Hip Replacement Implants - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
10. Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
11. Reportlinker Adds Hearing Aid Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Laboratory (IL) today announced the launch of its new corporate ... of a comprehensive rebranding effort by Werfen, the parent company ... , in 1959, IL has been part of the ... the group include Inova Diagnostics ( San Diego, CA ... ).  Like IL, these three companies are focused on ...
(Date:7/29/2014)... , July 29, 2014 Research and ... "Global Respiratory Devices Market 2014-2018" report to their ... A respiratory device is a medical device used ... having difficulty in breathing and cannot achieve adequate oxygen ... as cystic fibrosis, asthma, COPD, and ARDS require the ...
(Date:7/29/2014)... , July 29, 2014  Based on its ... (PERS) market, Frost & Sullivan recognizes MobileHelp with ... for Price Performance Value Leadership. MobileHelp,s leadership in ... expectations for tech progression in personal emergency response, ... these solutions. MobileHelp is at the ...
Breaking Medicine Technology:Instrumentation Laboratory Unveils New Corporate Brand 2Instrumentation Laboratory Unveils New Corporate Brand 3Global Respiratory Devices Market 2014-2018 2Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 2Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 3
(Date:7/30/2014)... WA (PRWEB) July 30, 2014 According to ... Vkool.com, this is a comprehensive guide that teaches people how ... few weeks. The book uncovers to readers the horrible truth ... in its review that inside this book, people will learn ... such as inflammation, asthma, and nasal infections. , Nasal Polyps ...
(Date:7/30/2014)... Kennewick, WA (PRWEB) July 30, 2014 ... today availability of over 80 different electronic therapy ... notes on tablets and other computing devices all ... 80+ therapy notes or electronic medial records (EMR) ... initial evaluations, and other essential categories. SOAP ...
(Date:7/30/2014)... Pain Free Living web: Superior Magnetics ... relief and improved performance. This new magnetic sports bracelet ... silicone core that is sheathed in nylon soaked in ... with scalar energy and Schumann frequency thus making it ... 12 years experience developing magnetic bracelets. We developed the ...
(Date:7/29/2014)... 2014 VisitandCare.com today announced ... added to the company’s exclusive network to help couples ... joint efforts — as top fertility clinics in Spain, ... affordable, state-of-the-art, and successful IVF treatments. , The exclusive ... comprehensive study by professionals at VisitandCare.com. The goal is ...
(Date:7/29/2014)... 30, 2014 Saint Luke’s Medical ... awarded the Patient-Centered Medical Home 2011 Level 3 ... for Quality Assurance. Only one out of four ... Level 2, or Level 3 recognition. , Patients ... Medical Home report faster access to their doctors, ...
Breaking Medicine News(10 mins):Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 2Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 3Health News:My Clients Plus Announces Over 80 Online Therapy Notes to Help Healthcare Providers Go Paperless 2Health News:Superior Magnetics Released New Magnetic Sports Bracelet for Pain 2Health News:Top European Fertility Clinics Join VisitandCare.com 2Health News:Top European Fertility Clinics Join VisitandCare.com 3Health News:Top European Fertility Clinics Join VisitandCare.com 4Health News:Saint Luke’s Medical Group Awarded Patient-Centered Medical Home 2011 Level 3 Recognition 2
... COSTA MESA, Calif., March 2 The deadliest wildfires ... 200 people and injured many more. Local medical institutions ... many with severe burns. The United States, largest tissue ... this crisis by providing skin to treat some of ...
... reason to eat your broccoli: UCLA researchers report that ... cruciferous vegetables may help protect against respiratory inflammation that ... pulmonary disease. , Published in the ... the research shows that sulforaphane, a chemical in broccoli, ...
... ARBOR, Mich., March 2 NanoBio Corp. announced today ... clinical and preclinical milestones in the development of its ... capitis. The new data will be delivered in five ... of Dermatology in San Francisco, March 6-9, 2009. In ...
... likely driven by limited availability of adolescent-only services , , ... percent of the 1.4 million American teens with substance ... study. , "Part of this treatment gap may ... services. Less than one-third of addiction programs in the ...
... more than half of MS patients are overweight or obeseWOONSOCKET, ... CVS ) today said it is working to help ... that found more than half of individuals with MS can ... recent review of CVS Caremark health management clients, plan participants ...
... The Healthcare business of Thomson Reuters has been ... its preferred vendor for mobile clinical quality improvement solutions. ... authorized to sell its Clinical Xpert(TM) suite of products ... the KLAS Category Leader for Mobile Data Systems for ...
Cached Medicine News:Health News:MTF, Largest Tissue Bank, Provides Skin for Victims of Australian Wildfires 2Health News:Broccoli may help protect against respiratory conditions like asthma 2Health News:NanoBio to Announce Key Clinical and Preclinical Data on Its Topical Anti-infective Lotions at AAD 2009 2Health News:Teens Undertreated for Substance Abuse 2Health News:CVS Caremark Health Management Programs Help Multiple Sclerosis Patients Better Manage Weight Issues and Improve BMI 2Health News:CVS Caremark Health Management Programs Help Multiple Sclerosis Patients Better Manage Weight Issues and Improve BMI 3Health News:VHA Selects Clinical Xpert from Thomson Reuters as its Preferred Solution for Mobile Clinical Improvement Systems 2Health News:VHA Selects Clinical Xpert from Thomson Reuters as its Preferred Solution for Mobile Clinical Improvement Systems 3
Aaron 2250 is a multipurpose electrosurgical generator with monoploar and bi-polar functions....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Designed to use all advantages of bipolar technique. C-2600 MP recommended to all specialties that uses the benefits of the bipolar techniques....
Medicine Products: